Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception?
Andrea S Licht, 1 Jill M Murphy, 2 Andrew J Hyland, 1, 3 Brian V Fix, 1 Larry W Hawk, 3, 4 Martin C Mahoney 1, 3 ABSTRACT Background Few studies have examined factors associated with the actual use of the human papillomavirus (HPV) vaccine since licensure in 2006. The aims of this study were to assess HPV vaccination rates and to examine whether knowledge and risk perceptions regarding HPV were associated with the reported use of the HPV vaccine among female college students. Methods Using a cross-sectional design, 406 women aged 18e26 years were recruited at two public universities and completed a self-administered survey.
Respondents who reported having received at least one dose of HPV vaccine were classified as 'vaccinated' (n¼177, 43.6%). Responses, stratified by the receipt of HPV vaccine, were compared using descriptive statistics and multivariate models.
Results Based on multivariate logistic regression modelling, 18-year-old women were approximately four times more likely to report use of the HPV vaccine compared with respondents aged 19e26 years. Respondents who correctly indicated that HPV caused genital warts were 1.85 times more likely (adjusted odds ratio (OR) 1.85, 95% CI 1.20 to 2.93) to have received at least one HPV vaccine. African American and Asian women were each less likely to be vaccinated compared with white women. Risk perception was not significantly associated with vaccine uptake, however, the majority of respondents failed accurately to recognise their high risk of both acquiring and transmitting HPV. Conclusions These findings suggest knowledge deficits and misperceptions about HPV risk as potential themes for educational campaigns encouraging the greater use of the preventive HPV vaccine among this subgroup.
Human papilloma viruses (HPV) represent one of the most common sexually transmitted infections, although less than half of the more than 100 HPV types infect mucosal (eg, genital, anal, oral) skin surfaces. 1 2 Although HPV infections remain prevalent across the lifespan, the prevalence of HPV infection peaks among young adults in their 20s, 1 which include many college-aged students. 3 Most infections are both transient and asymptomatic, generally resolving on their own. However, the disease burden of HPV is broad, including Papanicolaou test abnormalities, pre-cancers and cancers of the anogenital and head and neck regions, genital warts and recurrent respiratory papillomatosis. 1 2 4 5 Despite HPV being a ubiquitous infection, awareness of HPV among the general adult population in the USA continues to be limited. 6 7 Studies that explored the anticipated use of the HPV vaccine before its availability suggested that the intended use of this vaccine was associated with greater knowledge of HPV effects, including its association with cervical cancer, positive attitudes about the value of vaccination, approval from peers and a greater number of sexual partners. In the USA, a vaccine to prevent HPV infection has been approved for use (Gardasil; Merck, Whitehouse Station, New Jersey, USA) and another remains under review by the US Food and Drug Administration (Cervarix; GlaxoSmithKline, Rixensart, Belgium). Both vaccines, which consist of three injections administered over a 6-month interval, demonstrate impressive efficacy and mild, self-limited side effects. 14 15 The HPV vaccine (Gardasil, Merck) is recommended for use among women aged 9e26 years, with girls aged 11e12 years as a primary focus, along with vaccination of all girls and women aged 13e26 years and girls aged 9e10 years based on clinical preferences. 16 A recent survey indicated that 25% of girls aged 13e17 years have been vaccinated against HPV, 17 whereas fewer than 10% of women aged 18e26 years have received at least one dose of this vaccine. 18 Few studies have assessed factors associated with the actual use of the HPV vaccine since licensure of a preventive HPV vaccine (Gardasil; Merck) in June 2006. A study of sexually active girls and women aged 13e26 years, which explored factors associated with intended use, as well as actual HPV vaccination, was limited by the observation that just 5% of participants reported at least one dose of the HPV vaccine. 19 The aims of the present study were to assess rates of HPV vaccination and to examine whether knowledge and risk perceptions regarding HPV are associated with the reported use of the HPV vaccine among female college students.
METHODS

Design/study population
This study relied on a cross-sectional design whereby a convenience sample of participants was recruited from two universities. At university A, students were recruited from one of three 100-level general education classes, whereas at university B, students were recruited from the general psychology classes. As a result of differing institutional approaches to research, students at university A completed a self-administered questionnaire in the classroom setting, whereas students at university B completed an internet-based survey outside of class time, and were offered research credit towards the fulfilment of their course requirements. Records for women older than 26 years of age (n¼6) and participants who did not record their vaccination status (n¼2) were excluded. Respondents indicating no previous knowledge of HPV (n¼35) were also excluded, yielding a final total of 406 female students in the merged dataset.
Survey instrument
The survey contained sections on demographics, sexual and health behaviours, HPV vaccination, attitudes and perceptions regarding the HPV vaccine and a series of items on knowledge of HPV (see table 1 ). The core data items were identical at both universities. This research protocol was approved by each institution's Institutional Review Board and all participants provided assent.
Outcome measure
The main dependent variable was the self-reported completion of HPV vaccination. Those who reported having received at least one dose of HPV vaccine were classified as 'vaccinated' (n¼177, 43.6%), whereas those who reported not having received the HPV vaccine were classified as 'not vaccinated' (n¼229, 56.4%).
Covariates
Independent variables included demographic characteristics including school (university A, university B), age (18, 19e26 years), race (white, African-American, Asian, other), ethnicity (Hispanic, non-Hispanic) and religion (Protestant, Catholic, other, none).
Statistical analyses
Descriptive statistics and c 2 tests were used to explore associations between the dependent and independent variables.
Multivariate logistic regression models were constructed to explore correlates of receiving the HPV vaccine and included demographic variables, as well as knowledge items and the perceived risk of acquiring or transmitting HPV to others. All significance testing was based upon a p value of less than 0.05. Analyses were completed using SPSS V.14.0.
RESULTS
Overall, 43.6% of 406 female students reported having received at least one dose of HPV vaccine. Among those vaccinated, 15% reported receiving one dose, 33% reported two doses and 53% reported having completed the full three-dose series.
Selected demographic characteristics of the study population, stratified by vaccination status, are shown in table 2. Predictors of vaccination based on multivariate logistic regression modelling included age group and race. Female students aged 19e26 years were only approximately a quarter as likely to be vaccinated (adjusted odds ratio (OR) 0.27; 95% CI 0.17 to 0.41). AfricanAmericans and Asians were each less likely to be vaccinated compared with whites.
Respondents demonstrated high levels of knowledge for selected items on HPV disease outcome and transmission and the availability of a vaccine. Respondents were less knowledgeable about HPV as a cause of genital warts, HPV as a cause of penile cancer, transmission via skin-to-skin contact and that rates of HPV infection among men and women are comparable. Following adjustment in logistic models, respondents who correctly indicated that HPV caused genital warts were 1.85 times more likely (adjusted OR 1.85, CI 1.20 to 2.93) to have received at least one HPV vaccine. There were no other significant differences in HPV knowledge and vaccination status (see table 1 ). (table 3) . Overall, 22% of respondents rated their risk of acquiring HPV as 'high', 63% as 'low' and 15% 'did not know'. Similarly, the overall risk of transmitting HPV to others was rated as 'high' by 12%, 'low' by 67%, while 21% 'did not know'. After adjusting for demographic characteristics and the summary knowledge score, the perceived risk of HPV acquisition and transmission was not a predictor of HPV vaccination.
DISCUSSION
Our observation that 18-year-old female college students were approximately four times more likely to report HPV vaccination, compared to students aged 19e26 years, is probably related to these first-year college students having seen their primary care physicians before college matriculation when preventionoriented services, including vaccination, is generally encouraged. Physician recommendation remains as an important predictor of vaccination. 10 13 20 21 It is also possible that higher HPV vaccination rates among younger women could reflect greater parental control of healthcare decisions such as the receipt of vaccines.
The higher rate of HPV vaccination observed in this study (40%) may also be related to other factors. Previous studies assessing HPV vaccine rates collected data during a somewhat earlier time period allowing less time for vaccine 'uptake'. 11 18 19 Data from the National Immunisation Survey of adults in 2007, a more demographically heterogeneous sample, reported an HPV vaccination rate of 10% among women aged 19e26 years. 18 A 2007 survey of female college students at a north-eastern university reported an HPV vaccination rate of 12%. 11 Although our data are less generalisable than the national survey, the higher rate of HPV vaccination that we report suggests the possibility of a more generalised temporal increase in adherence with HPV vaccination recommendations. In addition, rates of vaccination among adolescents are generally higher than among young adults due to the availability of health insurance, use of the Vaccine For Children programme and/or greater use of healthcare services. Young adults face potential barriers to vaccination, including high out-of-pocket costs, lack of health insurance, and/or limited reimbursement, which warrant immediate attention. 22 23 The racial inequities in HPV vaccination we observed suggest that there may be differences in the effectiveness of vaccination programmes implemented through primary care, public (eg, Vaccine For Children programme), private and university programmes. The lower vaccination rate among African-American and Asian women compared with white women suggests a possible disparity in access to and use of preventive services, as well as possible differences in knowledge and understanding of HPV-related illnesses.
College women in this study demonstrated variable knowledge about HPV, which may partly explain limited HPV vaccination coverage among women aged 19e26 years. Whereas the majority of respondents in this study recognised that HPV is related to the occurrence of cervical cancer and abnormal Papanicolaou smears, a much lower proportion correctly indicated that genital warts are caused by HPV, that HPV cannot be cured and that condoms are not effective in preventing HPV transmission. It is not clear whether direct-to-consumer media campaigns, conversations with clinicians recommending the HPV vaccine, school-based educational programming and/or other factors might have contributed to knowledge of this specific HPV outcome.
Strengths and weaknesses
This study is noteworthy in that it is among the first to assess factors associated with the use of the HPV vaccine among a sample of college students since US Food and Drug Administration approval in 2006. Other strengths include a robust sample, its focus on college women, who remain an important target group for completion of vaccination, and an outcome measure that included any use of HPV vaccine and was not limited to only those women who completed the full three-dose series.
Limitations of this study include the use of a conveniencebased sample of women attending one of two public universities in New York State, the cross-sectional design and the lack of an objective measure to validate self-reported information on the completion of HPV vaccination.
CONCLUSIONS
This study among female college students demonstrated significantly lower utilisation of HPV vaccine among 19e26 year olds, and among African-Americans and Asians. However, we are unaware of others who have reported these observations and replication among other college populations is needed for validation. In general, knowledge of HPV infection, disease outcomes and transmission was variable. Recognition that HPV causes genital warts was associated with a higher rate of HPV vaccine use. Few respondents were able to report correctly that they were at high risk of both HPV acquisition and transmission, suggesting a modifiable barrier to greater use of the HPV vaccine. Taken together, these findings suggest potential themes for educational campaigns encouraging greater use of the preventive HPV vaccine among this population subgroup.
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